---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-022772"
form_type: "8-K"
ticker: "BCDA"
cik: "0000925741"
company_name: "BioCardia, Inc."
filed_at: "2025-07-16T23:59:59+00:00"
generated_at: "2026-05-18T06:24:36.786315+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Henry Ford Health enrolls first patients in BioCardia's Phase 3 CardiAMP HF II trial

## Summary
- Henry Ford Health (Detroit) is now enrolling ischemic HFrEF patients in BioCardia's pivotal CardiAMP HF II trial.
- CardiAMP HF II is a 250-patient randomized, placebo-controlled confirmatory study of autologous bone marrow cell therapy.
- Primary composite endpoint includes all-cause death, nonfatal MACE, and quality of life; prior CardiAMP HF trial met significance for elevated NTproBNP patients.
- Therapy involves same-day cell harvest, bedside processing, and minimally invasive catheter delivery.

## SEC filing metadata
- accession: 0001437749-25-022772
- form_type: 8-K
- ticker: BCDA
- cik: 0000925741
- company_name: BioCardia, Inc.
- filed_at: 2025-07-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/925741/000143774925022772/0001437749-25-022772-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/925741/000143774925022772/bcda20250716_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-022772
- JSON: https://secwatch.observer/filing/0001437749-25-022772.json
- Plain text: https://secwatch.observer/filing/0001437749-25-022772.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.